Medicare to negotiate prices for top drugs
Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, starting in 2027. These medications, used for conditions like diabetes, weight loss, and asthma, accounted for $41 billion in Medicare spending last year. Novo Nordisk’s drugs alone cost $14.4 billion.
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from cancer and type 2 diabetes to asthma.
Medicare Payment Advisory Commission recommends tying physician payment update to care cost growth; AMA calls for Congress to act on analysis.
Under legislation passed in 2022 called the Inflation Reduction Act, Medicare was allowed for the first time to negotiate prices with drug companies on a limited number of medications.
In 2025, more than 3 million seniors are going to save thousands of dollars because of a new spending limit on prescription drugs. It's unclear whether the Trump Administration will keep the law.
Hospitals are also seeing higher uncompensated care as individuals lose Medicaid coverage or decide not to purchase health insurance. If there are changes to the health insurance exchanges, more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback